WO2003006947A3 - Methode et composition de criblage cellulaire - Google Patents

Methode et composition de criblage cellulaire Download PDF

Info

Publication number
WO2003006947A3
WO2003006947A3 PCT/US2002/021339 US0221339W WO03006947A3 WO 2003006947 A3 WO2003006947 A3 WO 2003006947A3 US 0221339 W US0221339 W US 0221339W WO 03006947 A3 WO03006947 A3 WO 03006947A3
Authority
WO
WIPO (PCT)
Prior art keywords
transcription
methods
reporter enzyme
degradation
reporter
Prior art date
Application number
PCT/US2002/021339
Other languages
English (en)
Other versions
WO2003006947A2 (fr
Inventor
Sharat Singh
Po-Ying Chan-Hui
Original Assignee
Aclara Biosciences Inc
Sharat Singh
Po-Ying Chan-Hui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclara Biosciences Inc, Sharat Singh, Po-Ying Chan-Hui filed Critical Aclara Biosciences Inc
Priority to AU2002316577A priority Critical patent/AU2002316577A1/en
Publication of WO2003006947A2 publication Critical patent/WO2003006947A2/fr
Publication of WO2003006947A3 publication Critical patent/WO2003006947A3/fr
Priority to US10/740,079 priority patent/US20040175765A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes de criblage cellulaire multiplexé. On peut mettre en application ces méthodes afin de quantifier simultanément les niveaux de transcription de promoteurs ou de médicaments multiples ou de contrôler les effets exercés sur des interactions multiples protéine-protéine. Ces méthodes utilisent des produits de recombinaison de gènes rapporteurs couplant une seule séquence codante d'enzyme rapporteur à une ou plusieurs régions du promoteur, ainsi qu'un ensemble de sondes soumises à une dégradation par l'enzyme rapporteur, ce qui produit un ensemble de rapporteurs pouvant être séparés les uns des autres par leurs différences de mobilité. On exécute des essais multiplexés par combinaison d'un ensemble de population cellulaire, chaque population contenant un produit de recombinaison distinct de gène rapporteur et une sonde distincte. On exécute ensuite différents traitements sur le mélange de cellules. Les traitements induisant la transcription de promoteurs spécifiques provoqueront la synthèse de l'enzyme rapporteur dans une population cellulaire déterminée, ce qui conduit à la dégradation de la sonde correspondante. On détermine la génération des rapporteurs spécifiques par électrophorèse ou d'autres moyens de mesure de la mobilité et on la met en corrélation avec un effet du traitement sur la transcription d'un promoteur défini.
PCT/US2002/021339 2001-07-09 2002-07-05 Methode et composition de criblage cellulaire WO2003006947A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002316577A AU2002316577A1 (en) 2001-07-09 2002-07-05 Cell-screening assay and composition
US10/740,079 US20040175765A1 (en) 2002-07-05 2003-12-18 Cell-screening assay and composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30429601P 2001-07-09 2001-07-09
US60/304,296 2001-07-09
US32529201P 2001-09-27 2001-09-27
US60/325,292 2001-09-27

Publications (2)

Publication Number Publication Date
WO2003006947A2 WO2003006947A2 (fr) 2003-01-23
WO2003006947A3 true WO2003006947A3 (fr) 2003-05-08

Family

ID=26973933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021339 WO2003006947A2 (fr) 2001-07-09 2002-07-05 Methode et composition de criblage cellulaire

Country Status (2)

Country Link
AU (1) AU2002316577A1 (fr)
WO (1) WO2003006947A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K
US9110066B2 (en) 2009-01-15 2015-08-18 Laboratory Corporation Of America Holdings HER-3 antibodies and methods of use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087887A2 (fr) 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Complexes intracellulaires utilises comme biomarqueurs
CA2711843C (fr) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Procedes de diagnostic du her-2
WO2010065568A2 (fr) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings Procédés et dosages pour mesurer p95 et/ou p95 dans un échantillon et anticorps spécifiques de p95
WO2013138585A1 (fr) * 2012-03-16 2013-09-19 The Broad Institute, Inc. Procédés multiplex pour analyser simultanément des populations de cellules mélangées
WO2014053479A1 (fr) 2012-10-02 2014-04-10 Roche Diagnostics Gmbh Procédés permettant de libérer spécifiquement un sous-groupe d'objets
CA3016914C (fr) 2016-03-15 2019-08-27 Laboratory Corporation Of America Holdings Procedes d'evaluation d'interactions de proteines entre des cellules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725535A (en) * 1983-02-22 1988-02-16 Sonenshein Abraham L Promoter probe vectors
US5658736A (en) * 1996-01-16 1997-08-19 Genetics Institute, Inc. Oligonucleotide population preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725535A (en) * 1983-02-22 1988-02-16 Sonenshein Abraham L Promoter probe vectors
US5658736A (en) * 1996-01-16 1997-08-19 Genetics Institute, Inc. Oligonucleotide population preparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K
US9110066B2 (en) 2009-01-15 2015-08-18 Laboratory Corporation Of America Holdings HER-3 antibodies and methods of use

Also Published As

Publication number Publication date
AU2002316577A1 (en) 2003-01-29
WO2003006947A2 (fr) 2003-01-23

Similar Documents

Publication Publication Date Title
Sánchez-Vega et al. Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines
BR0010806A (pt) Métodos e materiais para a sìntese de produtos orgânicos
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
AU2003234196A1 (en) Functionalized nanoparticles and methods of use
NO20043259L (no) Bindingsproteiner som biosensorer
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
AR023229A1 (es) Polipéptidos mutantes, y su uso en composiciones detergentes.
WO2003104418A3 (fr) Polypeptides reconstitues
DE60137722D1 (de) Verwendung von mass-matched nukleotide in der analyse von oligonukleotidmischungen sowie in der hoch-multiplexen nukleinsäuresequenzierung
ATE338821T1 (de) Strukturprotein von aav, seine herstellung und verwendung
ATE384119T1 (de) Isoprenoidproduktion
BRPI0512798A (pt) molécula de ácido nucleico recombinante, célula, método para produzir uma proteìna de interesse, uso de uma seqüência de ácido nucleico tendo atividade anti-repressora, métodos para gerar uma célula hospedeira expressando dois polipeptìdios de interesse, e para expressar dois polipeptìdios de interesse
DE60043428D1 (de) POLYPEPTIDE MIT VERZWEIGUNGSENZYM-AKTIVITäT UND FüR DIESE KODIERENDE NUKLEINSäUREN
WO2003006947A3 (fr) Methode et composition de criblage cellulaire
ATE541924T1 (de) Selektion und isolierung lebender zellen unter verwendung rna-bindender sonden
WO2005033287A3 (fr) Methodes d'identification d'un produit genique a voie de synthese biologique
ATE380249T1 (de) Stabiele transfizierte zellen zum auffinden von wirkstoffen, die die mrna stabilität beeinflussen
ATE384787T1 (de) Tripeptidyl-aminopeptidase
DE602004029598D1 (de) Minimale dna sequenz, die als chromatin-isolator wirkt, und deren verwendung für die protein-expression
DE69934903D1 (de) Mitogene regulatoren
ITTR20030002A1 (it) Metodo per la rilevazione di coliformi ed in particolare
BR0313083A (pt) moléculas de adamts4 modificadas,polinucleotìdeo, vetor, processos para produção, composição farmacêutica, bem como uso das mesmas
ES2136284T3 (es) Adn que codifica el precursor de la proteinasa iii de cisteina relacionada con la enzima convertidora de interleucina 1-beta (icerel-iii).
WO2000028043A3 (fr) Polypeptides presentant une activite lactonohydrolase et acides nucleiques codant ces polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10740079

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP